Research programme: anti-SDF-1 antibodies - Medarex/OnoAlternative Names: Research programme: anti-stromal cell-derived factor-1 antibodies - Medarex/Ono
Latest Information Update: 29 Sep 2009
At a glance
- Originator Medarex; Ono Pharmaceutical
- Class Antibodies
- Mechanism of Action Chemokine CXCL12 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 29 Sep 2009 No development reported - Preclinical for Undefined indication in Japan (unspecified route)
- 29 Sep 2009 No development reported - Preclinical for Undefined indication in USA (unspecified route)
- 30 Mar 2006 Preclinical trials in Undefined in Japan (unspecified route)